PTCT Exec. VP and CLO Boulding Mark Elliott Sells $12K of Stock

Mark Boulding, Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT), sold 192 shares on October 9, 2026. The shares were sold for $64.26 each, totaling $12,337.92. This sale was part of a planned transaction.

Inside Boulding's Trade

Boulding's recent sale adds to his previous transactions, which included both buying and selling shares. His role as an executive at PTC Therapeutics highlights his significant involvement in the company's operations. This trade comes as the stock has been trading below its moving averages, suggesting some market challenges.

Other Institutional Activity in PTC Therapeutics

Several other institutional investors have also adjusted their positions in PTC Therapeutics. Blackrock Inc. increased its holdings by 1,016,428 shares, bringing its total to 13,964,554 shares valued at approximately $827.3 million. Jupiter Topco LLC saw a substantial change, adding 3,618,201 shares to hold a total of 7,236,402 shares worth about $428.7 million. Vanguard Portfolio Management LLC added 123,479 shares, raising its total to 4,928,111 shares valued at approximately $291.9 million.

PTC Therapeutics, Inc. Stock Down 2.9%

The stock of PTC Therapeutics recently traded around $59.22 as of October 16, 2026. This price is below both its 50-day moving average of $67.72 and its 200-day moving average of $71.49, indicating a potential downward trend. The stock is also about 34.8% below its 52-week high of $90.87, yet it remains 0.7% above its 52-week low of $58.80.

Recent Earnings

PTC Therapeutics reported a trailing twelve-month revenue of approximately $1.01 billion with a year-over-year revenue growth of 101.5%. However, the company has a negative net margin of -3.8%. The next earnings report is expected on October 29, 2026.

Insider Buying and Selling at PTC Therapeutics, Inc.

Earlier this year, Chief Technical Operations Officer Neil Gregory Almstead made several trades. On June 24, he bought 5,323 shares for $38.10 each, totaling $202,806.30. He also sold 5,323 shares on the same date under a planned sale for $85.03 each, amounting to $452,606.71. On June 26, he sold another 8,130 shares for $85.26 each, worth $693,151.60, and bought 8,130 shares for $38.10, totaling $309,753.00.

Analysts Set New Price Targets

Analysts have maintained their positive outlook on PTC Therapeutics. On July 31, 2026, Morgan Stanley maintained an Overweight rating with a price target of $104.0, up from $93.0. Wells Fargo followed suit on August 13, maintaining an Overweight rating and raising its target to $109.0 from $106.0. As of now, the consensus among analysts is a 'buy' with a mean price target of $100.33, based on 15 opinions.

About PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company based in Warren, NJ. It focuses on developing and commercializing medicines for rare disorders. This recent insider sale by Boulding comes as the company prepares for its next earnings report, reflecting ongoing adjustments in its executive team's stock holdings.

Bottom Line

Investors will be watching for PTC Therapeutics' upcoming earnings report on October 29, 2026. Mark Boulding's planned sale may indicate strategic moves within the company, and analysts remain optimistic about the stock's future performance despite recent trading challenges.